Blonanserin Therapy Improves Irritability in an Autistic Patient

この論文にアクセスする

この論文をさがす

著者

    • Kato Koji
    • Department of Psychiatry, Course of Specialized Clinical Science, Tokai University School of Medicine
    • Yamada Keigo
    • Department of Psychiatry, Course of Specialized Clinical Science, Tokai University School of Medicine
    • Akama Fumiaki
    • Department of Psychiatry, Course of Specialized Clinical Science, Tokai University School of Medicine
    • Saito Mai
    • Department of Psychiatry, Course of Specialized Clinical Science, Tokai University School of Medicine
    • Kimito Keitaro
    • Department of Psychiatry, Course of Specialized Clinical Science, Tokai University School of Medicine
    • Ohya Akitoshi
    • Department of Psychiatry, Course of Specialized Clinical Science, Tokai University School of Medicine
    • Matsumoto Hideo
    • Department of Psychiatry, Course of Specialized Clinical Science, Tokai University School of Medicine

抄録

Patients with autistic disorders (AD) exhibit irritability, aggression, deliberate self-injury, and tantrums, which often exacerbate social and communication problems and impair family life and/or school adjustments. Risperidone and aripiprazole have been approved by the U.S. Food and Drug Administration for treating irritability in children and adolescents with AD. The efficacy of other second-generation antipsychotics (SGA), such as quetiapine and olanzapine, for AD-associated irritability have been demonstrated in open-label trials. However, no study has yet evaluated the effectiveness and safety of blonanserin (BNS) for treating irritability in patients with AD in Japan. In this case report, we describe an AD patient who exhibited irritability while on standard antipsychotics that was improved by BNS. BNS may be effective and safe for treating AD-associated irritability. Further large-scale controlled studies will be needed to confirm our findings.

収録刊行物

  • Clinical Neuropsychopharmacology and Therapeutics

    Clinical Neuropsychopharmacology and Therapeutics 2(0), 9-11, 2011

    The Japanese Society of Clinical Neuropsychopharmacology

各種コード

  • NII論文ID(NAID)
    130000743682
  • 本文言語コード
    EN
  • ISSN
    1884-8826
  • データ提供元
    J-STAGE 
ページトップへ